Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Asset disposition
Revolution Medicines, Inc. (RVMD) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/13/2023 8-K Quarterly results
10/11/2023 144 Form 144 - Report of proposed sale of securities:
10/02/2023 EFFECT Form EFFECT - Notice of Effectiveness:
09/29/2023 DEFM14A Form DEFM14A - Definitive proxy statement relating to merger or acquisition:
09/29/2023 424B3 Form 424B3 - Prospectus [Rule 424(b)(3)]:
09/28/2023 144 Form 144 - Report of proposed sale of securities:
09/27/2023 S-4/A Form S-4/A - Registration of securities, business combinations: [Amend]
08/15/2023 144 Form 144 - Report of proposed sale of securities:
08/08/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/08/2023 8-K Quarterly results
Docs: "Revolution Medicines Reports Second Quarter 2023 Financial Results and Update on Corporate Progress Company to provide clinical updates for RMC-6236 at Triple Meeting and ESMO Congress 2023 and initial clinical findings for RMC-6291 at Triple Meeting Planning underway for one or more single agent pivotal trials with RMC-6236 and the first combination study of RMC-6236 and RMC-6291 Announced acquisition of EQRx, Inc. expected to add more than $1 billion in additional capital to balance sheet Webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., August 8, 2023"
08/02/2023 144 Form 144 - Report of proposed sale of securities:
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/01/2023 144 Form 144 - Report of proposed sale of securities:
08/01/2023 425 Form 425 - Prospectuses and communications, business combinations:
08/01/2023 8-K Quarterly results
07/31/2023 144 Form 144 - Report of proposed sale of securities:
06/30/2023 SC 13G BIOTECHNOLOGY VALUE FUND L P reports a 7.1% stake in Revolution Medicines, Inc.
06/16/2023 SC 13G/A EcoR1 Capital, LLC reports a 6.8% stake in Revolution Medicines, Inc.
06/09/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/08/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/08/2023 8-K Quarterly results
Docs: "Revolution Medicines Reports First Quarter 2023 Financial Results and Update on Corporate Progress First Wave of Investigational RAS Inhibitors – RMC-6236 , RMC-6291 and RMC-9805 – progressing on plan Appointment of chief medical officer and key leaders across late-stage development and commercial planning $909.8 million in cash, cash equivalents and investments at the end of first quarter 2023 Conference call and webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., May 8, 2023"
04/26/2023 ARS Form ARS - Annual Report to Security Holders:
04/26/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/26/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/07/2023 8-K Asset disposition
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Underwriting Agreement, among Revolution Medicines, Inc. and J.P. Morgan Securities LLC, Cowen and Company, LLC, SVB Securities LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein",
"Opinion of Latham & Watkins LLP"
03/01/2023 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
02/27/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/27/2023 10-K Annual Report for the period ended December 31, 2022
02/27/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress Early clinical data on RMC-6236 provided in support of RAS Inhibitor platform validation Additional data releases for RMC-6236 and RMC-6291 expected in 2023 RMC-9805 expected to begin clinical development in mid-2023 Growing pipeline of development-stage assets, including RMC-0708 , that target every major RAS cancer mutation hotspot Webcast today at 4:30 p.m. Eastern Time REDWOOD CITY, Calif., February 27, 2023"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy